192 Chapter 6 REFERENCES 1. Reedijk AMJ, Coebergh JWW, de Groot-Kruseman HA, et al. Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015. Leukemia. 2021;35(4):1001-1011. 2. Pound CM, Clark C, Ni A, Athale U, Lewis V, Halton JM. Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trial. J Pediatr Hematol Oncol. 2012;34(7):517-523. 3. McGrath P, Rawson-Huff N. Corticosteroids during continuation therapy for acute lymphoblastic leukemia: the psycho-social impact. Issues Compr Pediatr Nurs. 2010;33(1):5-19. 4. Day M, Harris S, Hussein D, et al. The efficacy of interactive group psychoeducation for children with leukaemia: A randomised controlled trial. Patient Educ Couns. 2021;104(12):3008-3015. 5. McGrath P, Pitcher L. ‘Enough is enough’: qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia. Support Care Cancer. 2002;10(2):146-155. 6. de Kloet ER. From receptor balance to rational glucocorticoid therapy. Endocrinology. 2014;155(8):2754-2769. 7. Kellner M, Wiedemann K. Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. Eur J Pharmacol. 2008;583(2-3):372-378. 8. Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151(3):397-406. 9. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000;21(1):55-89. 10. Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al. Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial. J Clin Oncol. 2016;34(19):22872293. 11. van Hulst AM, Verwaaijen EJ, Fiocco MF, et al. Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design. BMC Pediatr. 2021;21(1):427. 12. Netherlands Trial Register: https://www.trialregister.nl. https://www.trialregister.nl. Accessed. 13. Maurice-Stam H, Haverman L, Splinter A, van Oers HA, Schepers SA, Grootenhuis MA. Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) - parent form for children aged 2-18 years. Health Qual Life Outcomes. 2018;16(1):123. 14. van Widenfelt BM, Goedhart AW, Treffers PD, Goodman R. Dutch version of the Strengths and Difficulties Questionnaire (SDQ). Eur Child Adolesc Psychiatry. 2003;12(6):281-289. 15. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry. 1997;38(5):581-586. 16. Goodman R. Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry. 2001;40(11):1337-1345.
RkJQdWJsaXNoZXIy MTk4NDMw